Novartis acquires Arctos Medical
22 settembre 2021 – Novartis has acquired Arctos Medical, adding a pre-clinical optogenetics-based AAV gene therapy program and Arctos’ proprietary technology to its ophthalmology portfolio. Arctos developed its technology as a potential method for treating inherited retinal dystrophies (IRDs) and other diseases that involve photoreceptor loss, such as age-related macular degeneration (AMD).
Walder Wyss advised +ND Capital and the other sellers in the transaction. The team was led by Luc Defferrard (Partner, Corporate/M&A) and further included Dimitrios Berger (Senior Associate, Corporate/M&A), Janine Corti (Counsel, Tax) and Peter Bürkli (Senior Associate, Healthcare & Life Sciences).